Skip to main content
. Author manuscript; available in PMC: 2021 Feb 12.
Published in final edited form as: J Alzheimers Dis. 2020;78(3):989–1010. doi: 10.3233/JAD-200896

Table 3B.

Changes in ADAS-Cog following 12-month treatment with placebo or benfotiamine (ITT and per-protocol analysis)

Variable Total Placebo Benfotiamine p1
Unadjusted comparison of the changes from baseline to month 12 in ADAS score between intervention and control (ITT data after LOCF imputation)
ADAS score change Mean (SD) 2.37 (5.61) 3.26 (5.52) 1.39 (5.63) 0.162 [T]
Unadjusted comparison of the baseline to month 12 in ADAS score between benfotiamine and control (Per-protocol)
ADAS score change Mean (SD) 2.10 (5.59) 3.2 (5.66) 0.96 (5.41) 0.125 [T]

Repeated measures ANOVA p-value: 0.5626; Mixed effect model p-value: 0.0708; GEE p-value: 0.1373; Wilcoxon Rank sum p-value: 0.0980.

1

p-values obtained from the statistical tests: [T] t-test (equal variances). Repeated measures ANOVA p-value: 0.355; Mixed effect model p-value: 0.056; GEE p-value: 0.107; Wilcoxon Rank sum p-value: 0.069. p-values obtained from the statistical tests:[T] t-test (equal variances).